Source: CureToday articles
Eraglusib with gemcitabine and nab-paclitaxel achieved statistical significance in the first-line treatment of metastatic pancreatic ductal adenocarcinoma.
Recent Content
- Tyk2 Inhibition Prevents Islet Inflammation and Delays Type 1 Diabetes Development in Mice
- Specialty Pharmacy at a Crossroads, Say Attendees at Asembia’s AXS25 Summit
- Unmatched Energy, Every Single Day
- Expert Shares Key Insights During Melanoma Awareness Month
- AUC 5 vs AUC 6: MUSC Study Highlights the Tradeoffs in Neoadjuvant Breast Cancer Treatment
- Understanding AYA Lymphoma Care and Why Treatment May Differ by Age
- Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
- Study Finds Endometriosis May Be Linked to Traumatic Experiences
- FDA Approves Teal Wand, First At-Home Self-Collection Cervical Cancer Screening Device
- Eraglusib Combo Improves Survival in Metastatic Pancreatic Cancer